Chemomab Therapeutics Ltd. · NASDAQ:CMMB
Chemomab Therapeutics — Anchiano Therapeutics — Merger or Acquisition (January 2021)
19 slides from Chemomab Therapeutics's merger presentation, Jan 11, 2021
Slide 1: Pioneering Innovative Treatments for Fibrotic Diseases
Pioneering Innovative Treatments for Fibrotic Diseases Corporate Overview | Non-Confidential | January 2021
Slide 2: Forward Looking Statements
Forward Looking StatementsThis presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements include, among other things, statements regarding the clinical development pathway for CM-101; the proposed merger be
Slide 3: Chemomab Highlights: A Clinical Stage Biotech Company
Chemomab Highlights A Clinical Stage Biotech CompanyFocus • Development of innovative therapies for multiple fibrotic diseasesClinical Differentiation• CM-101, a first-in-class CCL24 neutralizing mAb with confirmed anti-fibrotic MoA • Validated CCL24 as critical fibrosis target: clinical findings an
Slide 4: Experienced Leadership
Experienced LeadershipManagementADI MOR, PhD Chief Executive Officer, Co-FounderARNON AHARON, MD Chief Medical OfficerSIGAL FATTAL, CPA Chief Financial OfficerSHARON ELKOBI, MSc, MBA VP Business DevelopmentMICHAL SEGAL-SALTO, PhD VP Research and DevelopmentSHARON HASHMUELI, PhD Head of CMC and Regul
Slide 5: Chemomab Strategy: Fibrotic Disease Franchise
Chemomab Strategy: Fibrotic Disease Franchise Addressing Fibrotic Diseases with High Unmet NeedINDICATIONCANDIDATEDISCOVERY PRECLINICALPHASE 1 PHASE 2 PIVOTALPRIMARY SCLEROSING CHOLANGITHISSYSTEMIC SCLEROSISCM-101 (IV) CM-101 (IV)Orphan designation granted from FDA and EMA Orphan designation granted
Slide 6: Fibrotic Diseases – Unmet Medical Need Potentiating High Morbidity and Mortality
Fibrotic Diseases – Unmet Medical Need Potentiating High Morbidity and MortalityFibrotic DiseaseOrphan DiseaseSOCSequelaMedian Survival7MM Prevalence ValuePrimary Sclerosing Cholangitis (PSC)Systemic Sclerosis (SSc)Symptomatic approach, UDCA (EU), Liver Transplant - the only disease modifying option
Slide 7: CCL24 is a Novel Therapeutic Target for Fibrosis
CCL24 is a Novel Therapeutic Target for Fibrosis Critical Mediator Promoting Inflammation and FibrosisCCL24-secreting cells M2 Macrophages, Immune and Epithelial cellsCCL24CCL24-regulated cells Fibroblasts-Liver, Lung and skin, Immune cells, and Cholangiocyte Dual role in promoting fibrosis - direct
Slide 8: CCL24: a Critical Node Potentiating Fibrosis-Related Diseases
CCL24: a Critical Node Potentiating Fibrosis-Related Diseases Target Validation in PSC and SScCCL24 level in SSc patients’ skinCCL24 level in SSc patients’ serumCCL24 serum level in PSC patients correlates with ELF fibrotic biomarkerCCL24 level in PSC patients’ liverGreen-CCL24; Red-CD31Collaboratio
Slide 9: CCL24 Blockade is Singularly Sufficient to Attenuate Fibrosis
CCL24 Blockade is Singularly Sufficient to Attenuate Fibrosis Knocking out the CCL24 gene attenuates bleomycin Induced (SSc) model1.81.6Dermal thickness*Immune cell lung infiltration50001.41.210.84000300020001000*0.6WT PBS WT BLM CCL24 KO- PBSCCL24 KO- BLM0 WT-BLM CCL24 KO-BLMCCL24 KO-BLMCCL24 KO-PB
Slide 10: CM-101- A First in Class mAb Blocking CCL24
CM-101- A First in Class mAb Blocking CCL24 Dual Mechanism of Action Interfering with the Core Fibrotic Pathways CM-101 Fully humanized antibody, binds and blocks CCL24 withCCR3CCL24high affinity CM-101’s epitope directly interfering with Receptor-InflammationImmune cells recruitmentFibrosisFibrobla
Slide 11: CM-101 Reduces Liver Fibrosis by 80%
CM-101 Reduces Liver Fibrosis by 80% Reduced Liver Collagen in TAA Liver Fibrosis Rat Model Using Therapeutic DesignSIRIUS RED (COLLAGEN)10080604020082% reductionTAA TAA +CM-101 (2.5mg/kg)Pro-fibrotic genesLiver enzymesCol1A1 Col3A1 TIMP1 ACTA2 TGF-βALT AST ALPSegal-Salto et al, JHEP reports 2020Non
Slide 12: CM-101 Profoundly Reduces Skin and Lung Fibrosis in SSc
CM-101 Profoundly Reduces Skin and Lung Fibrosis in SSc Skin and Lung Experimental Models Relevant to Systemic Sclerosis Using Therapeutic DesignBleomycin (SC) induced dermal fibrosis100Normalizes skin and lung fibrosis levels in bleomycin induced models using therapeutic dosing after disease eviden
Slide 13: CM-101 Holds a Robust Preclinical Package
CM-101 Holds a Robust Preclinical Package Significantly Attenuates Fibrosis & Inflammation Across a Wide Range of ModelsCCL24 Target ValidationEx-Vivo (Patient Samples) PSC • Biomarkers correlation • Overexpression of CCL24 and CCR3 Systemic Sclerosis • Fibrotic biomarkers correlation • Disease dete
Slide 14: CM-101 is Safe & Well Tolerated in Healthy Volunteers
CM-101 is Safe & Well Tolerated in Healthy Volunteers Phase 1a Single Administration study• CM-101 was safe and well tolerated at all tested doses up to 10 mg/kg and for both formulations• Average t1/2 of 19-21 days (for IV and SC), supports long interval administration once every 2-4 weeks• Dose de
Slide 15: Ph1b Demonstrates Safety & Tolerability Along Weeks Treatment
Ph1b Demonstrates Safety & Tolerability Along 15 Weeks Treatment Phase 1b Multiple Administration Study in NAFLD Patients• Study population- NAFLD patients with normal liver functionDouble-Blind, Randomized Escalating Dose (N=16)• Multiple CM-101 administrations were safe and well tolerated using bo
Slide 16: CM-101 Target Engagement & Anti-Fibrotic Mechanism
CM-101 Target Engagement & Anti-Fibrotic Mechanism Human Confirmation for CM-101 Anti-Fibrotic Mechanism of ActionPK-PDFibrotic Biomarkers* & ElastographyPK-PD 2.5mg/kg IV 2520151050 0 21 42 63 84 105 126CCL24 (Target Eng.) CM-101150100 10 2050 10 00 0CM-101 Placebo30150Time (days) 60 PK-PD 5mg/kg S
Slide 17: CM-101 Clinical Development Plan and Key Catalysts
CM-101 Clinical Development Plan and Key Catalysts Phase 2 Studies Driving Pivotal Studies2020 2021 2022Primary Sclerosing Cholangitis (IV formulation)Phase 2: 12 wk treatment *Randomized placebo-controlled; Europe and Israel study sitesFPI Q4/20IA LPI Q4/21POCSystemic Sclerosis (IV formulation)Phas
Slide 18: Chemomab, Fighting Fibrosis Across Indications
Chemomab, Fighting Fibrosis Across IndicationsOpportunity Clinical stage company entering Ph2 trials in multiple fibrotic indications with high unmet need Substantial value inflection points in 2021-2022 Strong leadership with proven track recordCM-101 First-in-class mAb blocking CCL24 Novel and dif
Slide 19: Presentation name
Presentation name
Anchiano Therapeutics — Merger or Acquisition (January 2021) on 6ix